Trisomy 4 Identifies a Subset of Acute Nonlymphocytic Leukemias

By Cristina Mecucci, Angeline Van Orshoven, Guido Tricot, Jean-Louis Michaux, André Delannoy, and Herman Van Den Bergh

We present four patients with acute nonlymphocytic leukemia, one M2 and three M4 French-American-British (FAB) types and one patient with refractory anemia with excess of blasts in transformation who at diagnosis had trisomy of chromosome 4 as the primary karyotypic anomaly. This chromosome anomaly probably defines a previously undescribed subset of acute nonlymphoid leukemia. Hematologic characteristics commonly found in these patients were dysplastic features of all bone marrow lineages, suggesting that trisomy 4–associated disorders involve the early myeloid hematopoietic stem cell.

© 1986 by Grune & Stratton, Inc.

From the Centers of Human Genetics and Hematology, University of Leuven, Centre d’Hematologie, University of Louvain in Brussels, and Service d’Hematologie, Hopital de Jolimont, Belgium.

Submitted Sept 9, 1985; accepted Dec 21, 1985.
Address reprint requests to Dr Cristina Mecucci, Center for Human Genetics, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

© 1986 by Grune & Stratton, Inc.
0006-4971/86/6705-0023$03.00/0

**Table 1. Clinical Data of the Patients and Morphologic, Cytochemical, and Antigenic Characteristics of Their Blast Cells at the Time of Chromosome Investigation**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/Sex</th>
<th>Date</th>
<th>FAB Type</th>
<th>HB (g/dL)</th>
<th>Platelets (x 10^9/L)</th>
<th>WBC (x 10^9/L)</th>
<th>Cytochemistry*</th>
<th>Immunophenotype†</th>
<th>Survival From Diagnosis (mo)</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>N.V.C.</td>
<td>17/F</td>
<td>April 1974</td>
<td>M2</td>
<td>10.4</td>
<td>90</td>
<td>33.7</td>
<td>BM 43</td>
<td>Promyelocytes (%)</td>
<td>PAS POX SBB ANBE ANAE</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ND ND ND ND ND</td>
<td>ARA-C 6-TG</td>
</tr>
<tr>
<td>H.B.</td>
<td>64/F</td>
<td>June 1984</td>
<td>M4</td>
<td>11.7</td>
<td>54</td>
<td>18.7</td>
<td>BM 51</td>
<td>4</td>
<td>ND 40 50 ND ND</td>
<td>TdT-neg, BA-2-pos, OKT10-pos, OKT3-neg, Slg-neg</td>
</tr>
<tr>
<td>A.Z.</td>
<td>56/F</td>
<td>June 1978</td>
<td>M4</td>
<td>9</td>
<td>17</td>
<td>248</td>
<td>BM 89</td>
<td>9</td>
<td>0 0 10 49 ND</td>
<td>—</td>
</tr>
<tr>
<td>J.M.</td>
<td>15/M</td>
<td>Oct 1984</td>
<td>M4</td>
<td>7.6</td>
<td>31</td>
<td>4.7</td>
<td>BM 87</td>
<td>2</td>
<td>0 40 ND 30 ND</td>
<td>TdT-neg, OKT1a1-pos, OKMS-pos</td>
</tr>
<tr>
<td>P.B.</td>
<td>58/F</td>
<td>Oct 1984</td>
<td>RAEBt</td>
<td>8</td>
<td>199</td>
<td>15.8</td>
<td>PB 22</td>
<td>—</td>
<td>0 ND 8 ND 2</td>
<td>TdT neg, BA-1-neg, B1-neg, J5-neg, OKT3-neg, OKT1a1-pos, OKT9-pos, OKT10-pos</td>
</tr>
</tbody>
</table>

Abbreviations: BM, bone marrow; PB, peripheral blood; RAEBt, refractory anemia with excess of blasts in transformation; ARA-C, cytosine arabinoside; 6-TG, 6 thioguanine; Adria, Adriamycin; Dauno, daunomycin; 6-MP, 6-mercaptopurine; ND, not determined.

*Numbers indicate positive cells among blast cells.

†Reactivity of monoclonal antibodies: TdT, lymphoid progenitor cells; BA-1, pre-B cells, B cells, granulocytes; BA-2, pre-B and B cells; vast majority of non-T acute lymphocytic leukemia (ALL), some cases of nonlymphoid leukemias; B1, pre-B, B cells; J5, common ALL antigen; OKT1a1, HLA-DR antigens, B cells, macrophages, activated T cells; OKT3, mature T cells; OKT9, transferrin receptor, proliferating cells, including stem cells and activated lymphocytes; OKT10, early stem cells, activated lymphocytes; OKMS, monocytes and platelets.
hemoglobin, $157 \times 10^9$/L platelets, and $9.4 \times 10^9$/L WBC with 19% blast cells.

**Morphologic and cytochemical studies.** May-Grünwald-Giemsa (MGG)-stained slides of bone marrow and peripheral blood were reviewed retrospectively in all the cases using the criteria of the French-American-British (FAB) classification for acute leukemias and myelodysplastic syndromes.62 Cytochemical studies included assays for periodic acid–Schiff stain (PAS), Sudan black B (SBB), peroxidase (POX), alpha-naphthyl-acetate-esterase (ANAЕ), and alpha-naphthyl-butylate esterase (ANBE) and were performed following the usual criteria.17

**Immunologic marker studies.** Surface markers were detected by an indirect immunofluorescence technique using fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG (Ortho Pharmaceutical Corp, Raritan, NJ) as the second antibody. Cell surface immunoglobulins were tested by direct fluorescence with FITC-conjugated antibodies.

Monoclonal antibodies OKT1α, OKT3, OKT9, OKT10, OKM5 (Ortho Pharmaceuticals), BA-1, BA-2 (Hybritech, San Diego), B1, and J5 (Coulter Immunology, Hialeah, Fl) were obtained commercially. Reactivity is reported in Table I. Terminal deoxynucleotidyl transferase (TdT) activity was determined by immunofluorescence using rabbit anti-TdT serum and FITC-conjugated goat antirabbit-serum (Bethesda Research Laboratories, Md).

**Cytogenetic studies.** Chromosome analysis was performed at diagnosis on all patients. Metaphase chromosome preparations were obtained from bone marrow and/or peripheral blood cells after 48-hour unstimulated cultures. A reverse banding with acridine orange was used. Karyotypes were arranged according to the International System for Human Cytogenetic Nomenclature.18

**RESULTS**

**Morphologic, cytochemical, and immunologic studies.** The age, sex, presenting symptoms, WBC count, hemoglobin level, platelet count, cytochemical properties and immunophenotype of blast cells, type of treatment, and survival from diagnosis of the five patients with trisomy 4 are listed in Table 1.

**Patient N.C.V.** was classified as FAB M2 on the basis of the presence of maturation of the bone marrow cells, including granulated myeloblasts, Auer’s rods, and a high number of promyelocytes. Pelger-Huët–like anomaly, megaloblastic features of the red cell series, and a very few, abnormal megakaryocytes were noted.

**Patient H.B.** was classified at diagnosis as M4. MGG-stained slides of bone marrow showed maturation of the myeloid blasts and a few elements with single Auer’s rods. Nuclear abnormalities with bilobated or clover nuclei were prominent in the blast elements. Bone marrow smears showed 30% of the blast cells positive for ANAE. The more differentiated granulocytic forms showed a Pelger-Huët–like anomaly as well as hypersegmentation. A few eosinobasophilic elements were also observed. The red cell series was megaloblastic, and several binucleated forms were present. Megakaryocytes were abnormal with monolobulated nuclei and cytoplasmic basophilia. Blast cells in this case reacted with the BA-2 monoclonal antibody. All other lymphoid markers, however, were negative, including TdT, T3 antigen, and surface immunoglobulins.

In patient A.Z., bone marrow was classified as M4 and showed abnormal maturation of the myeloid series with hypogranulation. Pelger-Huët–like anomaly was present. Several blast cells showed scanty cytoplasm and sometimes folded nuclei. Most of these elements (49%) showed ANBE activity partially inhibited by NaF. Megaloblastosis of red cell series, hypolobulation of megakaryocytes, and a few eosinobasophils were associated morphologic anomalies.

Patient J.M. showed a typical FAB M4. ANBE activity was present in 30% of the immature elements. Morphologic anomalies, ie, megaloblastosis of the red cell series, dysmegakaryopoiesis, Pelger-Huët–like anomalies, and eosinobasophilic elements were consistently present in this case.

In patient P.B., the diagnosis was RAEB2 in Oct 1984 when cytogenetic studies were performed. Morphologically, two types of blast cells were identified: small blast elements with scanty cytoplasm, diffuse nuclear chromatin, and one or sometimes two nuclei; and blasts with folded monocytoid nuclei. There was abnormal maturation of the myeloid series with a Pelger-Huët–like anomaly. Dysmegakaryopoiesis was present with both monolobulated and apparently polylobulated forms. The red cell series was megaloblastic. Iron staining did not show ringed sideroblasts. Plasma cells and eosinobasophils were noted. The myeloid nature of the disorder in this patient was confirmed by positivity of the SBB stain in more than 5% of the blast cells. Moreover, immunophenotype studies revealed a negativity of the antibodies reacting with lymphoid antigens, ie, TdT, BA-1, B1, J5, and OKT3.

**Cytogenetic studies.** The karyotypic investigations of the five patients at diagnosis and during the course of the disease are summarized in Table 2. Figure 1 shows the trisomy 4 in a partial karyotype of the five patients. In patients 1, 2, and 4, the predominant clone with trisomy 4 was associated with normal karyotypes at the time of diagnosis. In patient 1, no mitoses were obtained at the time of a possible hematologic remission, but trisomy 4 was again present in 80% of the bone marrow metaphases during the terminal phase of the disease. Patient 3 showed trisomy 4 as sole anomaly in 23 out of 25 metaphases. In this patient, however, also one subclone with an additional trisomy 7 was identified. All five metaphases obtained from the peripheral blood of patient 5 showed a 47, XX, +4 karyotype.

**DISCUSSION**

To the best of our knowledge, trisomy 4 as the primary karyotypic anomaly has never been described in human hematologic malignancies. A few cases of ANLL, namely, one M2 and five M5 FAB types have been described in which trisomy 4 was part of a complex abnormal karyotype with both numerical and structural anomalies of other chromosomes.19-21

The present study documents for the first time the existence of a unique hematologic disorder associated with a trisomy of chromosome 4. This hematologic disorder is nonlymphoid in nature as demonstrated on the basis of morphology, cytochemistry, and monoclonal antibody reactivity of the blast cells. Furthermore, the fact that the acute leukemias in this study showed either granulocytic or monocytic differentiation, ie, M2 and M4 FAB types, indicates...
that at least the common granulomonocytic progenitor cell was involved. Yet, from this study two lines of evidence suggest that an early myeloid precursor, possibly the myeloid hematopoietic stem cell, multipotent for erythrocytes, platelets, granulocytes, and monocytes, was the primary site of lesion for the trisomy 4–associated disorders. First, in all our cases of ANLL, namely, one M2 and three M4, the erythrocytic and megakaryocytic cells showed a marked dysplasia consistent with the involvement of both these series in the neoplastic process. Fialkow and colleagues\textsuperscript{23} using G6PD isoenzyme studies, have demonstrated that ANLLs with such morphologic features arose from a pluripotent myeloid cell. Furthermore, the last patient of our series showed a myelodysplastic syndrome that is a disorder of a pluripotent stem cell according to both morphologic and enzymatic studies.\textsuperscript{24,25} Trisomy 4 thus probably arises in a myeloid totipotent stem cell that maintains the capacity of differentiating along the granulocytic and monocytic pathways. Dysplasia of the three bone marrow cell lines is often observed in cases of ANLL or myelodysplastic syndrome arising in patients who have a history of occupational exposure to toxics or prior cytotoxic therapy.\textsuperscript{26} Our five patients with trisomy 4, however, were not professionally exposed to toxics. Moreover, in all our cases, cytogenetic studies were performed before any chemotherapy.

Finally, on the basis of our experience and previously reported large series of ANLL patients,\textsuperscript{12,27} trisomy 4 associated disorders appear to be uncommon. In our cases, however, the trisomy 4 was found after 48 hours of culture, which is rarely used in cytogenetic laboratories. This culture method might be especially suitable in determining the trisomy 4 anomaly.

The significance of a trisomy of chromosome 4 for the biology of the malignant clone is unclear at present. Trisomy may be associated with quantitative changes in the production of specific gene products. A gene dosage effect has been described in some disorders associated with trisomy 8 and increased levels of the enzyme glutathione reductase, the gene of which is located on the short arm of chromosome 8.\textsuperscript{28,29} A similar example was recently given by Koprowski et al\textsuperscript{30} who demonstrated that the epidermal growth factor receptor, coded for by chromosome 7, was expressed by only melanoma cells with a trisomy 7. Therefore, one may speculate that trisomy 4 is involved in the abnormal proliferation of the neoplastic clone through an increased production of one or more factor(s) that are controlled by genes on this chromosome. Two genes involved in the proliferation and self-perpetuation of malignant cells\textsuperscript{31} have been mapped on chromosome 4, one coding for the T cell growth factor,\textsuperscript{32} the other for the epidermal growth factor.\textsuperscript{33} It remains to be tested whether trisomy 4 confers a proliferating advantage to the malignant cells by amplification of one or more of these growth factor(s).
REFERENCES

22. Dewald G, Morrison-Dehop SJ, Schuchard KA, Spurbeck JL, Pierre R: A possible specific chromosome marker for mononcytic leukemia: Three more patients with t(9;11)(p22;q24) and another with t(11;17)(q24;q21), each with acute monoblastic leukemia. Cancer Genet Cytogenet 8:203, 1983
Trisomy 4 identifies a subset of acute nonlymphocytic leukemias
C Mecucci, A Van Orshoven, G Tricot, JL Michaux, A Delannoy and H Van den Berghe

Updated information and services can be found at:
http://www.bloodjournal.org/content/67/5/1328.full.html
Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml